BESTSELLER

Next-generation Sequencing (NGS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Next-generation Sequencing Market is segmented by Type of Sequencing (Whole Genome Sequencing, Targeted Resequencing, Whole Exome Sequencing, RNA Sequencing, CHIP Sequencing, De Novo Sequencing, and Methyl Sequencing), Product Type (Instruments, Reagents and Consumables, and Services), End User (Hospitals and Healthcare Institutions, Academics, and Pharmaceutical and Biotechnology Companies) Application (Drug Discovery and Personalized Medicine, Genetic Screening, Diagnostics, Agriculture and Animal Research, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the market size and forecasts in value (USD million) for the above segments.

Market Snapshot

next generation sequencing ngs market
Study Period:

2018-2026

Base Year:

2020

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

19.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The next-generation sequencing market was valued at about USD 7,580 million in 2020, and it is expected to reach approximately USD 18,550 million in 2026, registering a CAGR of nearly 19.1% over the forecast period, 2021-2026.

Next-generation sequencing (NGS) diagnostic technology has the potential advantage of determining the genetic sequence of a virus and helping scientists understand the mutation of the virus. Throughout the COVID-19 pandemic, government authorities across the world are constantly working with the private sector to bring NGS technology as the potential diagnostic tool in the market. In June 2020, the United States Food and Drug Administration (US FDA) issued an emergency use authorization (EUA) to Illumina Inc. for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA.

The major factors such as increasing research and development activities utilizing the NGS technologies, growing applications of NGS in clinical diagnosis, and discovery applications demanding NGS technology are expected to drive the growth of the overall market.

In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided USD 23 million to the Broad Institute and Harvard University and DNA Script. The organizations have been working together to explore the possibility of combining the enzymatic DNA synthesis technology and NGS into a single instrument for more than four years. Such developments are a major boost to the clinical studies and organizations progressing with NGS as their basis of innovation.

In the recent past, NGS has been considered the most potent tool in diagnostics and in researches to understand the treatment regimen for various diseases, including cancer, infectious diseases, cardiovascular diseases, etc. According to the United States National Institutes of Health, National Human Genome Research Institute, in 2017, most of the rare diseases were genetic in nature. There has been continuous progress in understanding diseases at the genomic level and molecular level, and various companies are deploying resources in the testing of these diseases to leverage opportunities which is also fueling the market opportunities. For instance, in August 2020, GeneDx Inc., a subsidiary of BioReference Laboratories Inc., and OPKO Health entered an agreement with Pediatrix Medical Group to offer state-of-the-art, next-generation genomic sequencing to support clinical diagnosis in rare diseases for neonatal intensive care units. Also, in 2017, Myriad Genetics Inc. launched the EndoPredict test for patients with ER+ HER2- early-stage breast cancer.

The rapid speed, cost, and accuracy of the NGS technology have also helped in the growth of the market. However, the current market is facing challenges due to the difficulty in the management of large data and complications associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people, are pulling back the growth of the market.

Scope of the Report

As per the scope of this report, NGS is a technology in which millions of DNA strands can be sequenced through massive parallelization; this technique is also known as high throughput sequencing. The low cost, high accuracy and speed, and precise results even from low sample inputs are the main advantages NGS offers over Sanger’s sequencing method. The market is segmented by type of sequencing (whole genome sequencing, targeted resequencing, whole-exome sequencing, RNA sequencing, CHIP sequencing, de novo sequencing, and methyl sequencing) product type (instruments, reagents and consumables, and services), end user (hospitals and healthcare institutions, academics, and pharmaceutical, and biotechnology companies) application (drug discovery and personalized medicine, genetic screening, diagnostics, agriculture and animal research, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers market size and forecasts in value (USD million) for the above segments.

By Type of Sequencing
Whole Genome Sequencing
Targeted Resequencing
Whole Exome Sequencing
RNA Sequencing
CHIP Sequencing
De Novo Sequencing
Methyl Sequencing
By Product Type
Instruments
Reagents and Consumables
Services
By End User
Hospitals and Healthcare Institutions
Academics
Pharmaceutical and Biotechnology Companies
By Application
Drug Discovery and Personalized Medicine
Genetic Screening
Diagnostics
Agriculture and Animal Research
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Whole Genome Sequencing Segment is Expected to Grow at a Good Rate Over the Forecast Period

By type of sequencing, whole-genome sequencing is expected to grow positively. Whole-genome sequencing (WGS) has been widely accepted in providing the highest possible resolution information about COVD-19 and is believed to have the potential to transform COVID-19 infectious disease management. For instance, in earlier 2020, the UK government launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. The COVID-19 Genomics UK Consortium (COG-UK) is comprised of the NHS (National Health Service), public health agencies, the Wellcome Sanger Institute, and several academic institutions, helping in creating funds and developing diagnostics and treatment. In the United States, the National Institutes of Health is one of the primary organizations supporting innovative studies via sequencing by growing funds for the same.

Also, there are various technological advancements in the field of whole-genome sequencing, fueling the market growth. For instance, in February 2019, Machaon Diagnostics launched a 48-hour STAT Hemophagocytic Lymphohistiocytosis (HLH) Genetic Panel, one of the fastest NGS genetic testing panels for Hemophagocytic Lymphohistiocytosis, a rare disease in young children and infants due to cancer. Such developments by the major players and their collaborations with innovative upcoming companies in sequencing and diagnostics are propelling the growth of the whole genome sequencing segment of the market.

Funding

To understand key trends, Download Sample Report

North America is Expected to Hold a Major Share of the Market in the Forecast Period

Next-generation sequencing (NGS) technology is gaining popularity as a routine clinical diagnostic test, particularly with the COVID-19 pandemic in this region. For instance, in August 2020, Helix Laboratory received the United States Food and Drug Administration approval for its COVID-19 NGS test, which is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens for COVID-19 suspected individuals.

North America is expected to hold the largest share in the NGS market. The rising focus of the major market players is on delivering advanced, efficient NGS technologies to developing countries to cater to the need for genomic medicines and whole-genome sequencing for personalized medicine. For instance, in January 2018, Thermo Fisher introduced the upgraded Ion AmpliSeq Exome RDY kit that enables cost-effective, rapid identification of copy number variations, small insertions, or deletions. These advanced technologies assist in understanding heritability and complex disorders, thereby favoring DNA sequencing growth in the forthcoming future.

In addition, the increasing adoption of NGS technology by the non-government and government bodies, along with increased funding by the federal government and the private players, is expected to drive the market growth. The National Human Genome Research Institute has launched the National Human Genome Research Institute (NHGRI) Genome Technology Program and Advanced DNA Sequencing Technology awards to provide funding and research support to players to develop advanced and novel NGC technologies.

All these developments, along with the rising healthcare expenditure and increasing geographic footprints of the players, are driving the growth of the market in this region.

Next-generation Sequencing (NGS) Market

To understand geography trends, Download Sample Report

Competitive Landscape

Strategic mergers and acquisitions and new product launches are the key strategies of the players in this market. Some of the developments that happened in the recent past are:

In 2019, Saphetor SA partnered with Swift Biosciences Inc. to standardize and accelerate the data interpretation solutions for next-generation sequencing panels. Further, in 2019, Qiagen launched NGS panels and liquid biopsy solutions with integrated bioinformatics to lead advances in cancer research. Also, in 2019, PierianDx signed a partnership agreement with Illumina Inc. to support cancer diagnostics and research. Each year, there are several companies collaborating to benefit and provide the best output of results from new technologies in the NGS market. These developments are enabling the companies to expand their market presence and are helping them gain a competitive advantage, thereby propelling the market growth.

Recent Developments

In September 2020, Illumina Inc. acquired GRAIL, a healthcare company focused on multi-cancer early detection, for cash and stock consideration of USD 8 billion upon closing of the transaction.

In August 2020, Guardant Health Inc. received the United States Food and Drug Administration (FDA) approval for Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor).

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Applications in Clinical Diagnosis

      2. 4.2.2 Speed, Cost, and Accuracy to Spur the Market Growth

      3. 4.2.3 Efficient Replacement for Traditional Technologies (Microarrays)

      4. 4.2.4 Drug Discovery Applications Demanding NGS Technology

    3. 4.3 Market Restraints

      1. 4.3.1 Legal and Ethical Issues

      2. 4.3.2 Interpretation of Complex Data and Lack of Skilled Professionals

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Sequencing

      1. 5.1.1 Whole Genome Sequencing

      2. 5.1.2 Targeted Resequencing

      3. 5.1.3 Whole Exome Sequencing

      4. 5.1.4 RNA Sequencing

      5. 5.1.5 CHIP Sequencing

      6. 5.1.6 De Novo Sequencing

      7. 5.1.7 Methyl Sequencing

    2. 5.2 By Product Type

      1. 5.2.1 Instruments

      2. 5.2.2 Reagents and Consumables

      3. 5.2.3 Services

    3. 5.3 By End User

      1. 5.3.1 Hospitals and Healthcare Institutions

      2. 5.3.2 Academics

      3. 5.3.3 Pharmaceutical and Biotechnology Companies

    4. 5.4 By Application

      1. 5.4.1 Drug Discovery and Personalized Medicine

      2. 5.4.2 Genetic Screening

      3. 5.4.3 Diagnostics

      4. 5.4.4 Agriculture and Animal Research

      5. 5.4.5 Other Applications

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Agilent Technologies

      2. 6.1.2 Bio-Rad Laboratories Inc.

      3. 6.1.3 DNASTAR Inc.

      4. 6.1.4 Eurofins Scientific

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Illumina Inc.

      7. 6.1.7 Macrogen Inc.

      8. 6.1.8 Pacific Biosciences of California Inc.

      9. 6.1.9 PerkinElmer Inc.

      10. 6.1.10 Qiagen

      11. 6.1.11 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Next-generation Sequencing (NGS) Market market is studied from 2018 - 2026.

The Global Next-generation Sequencing (NGS) Market is growing at a CAGR of 19.1% over the next 5 years.

The Global Next-generation Sequencing (NGS) Market is valued at 7580 Million USD in 2018.

The Global Next-generation Sequencing (NGS) Market is valued at 18550 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • Agilent Technologies
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc.
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.

Are the major companies operating in Global Next-generation Sequencing (NGS) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!